Skip to main content
ARS Home » Research » Publications at this Location » Publication #203306

Title: Newcastle disease virus vaccine potency determination

item Liljebjelke, Karen
item King, Daniel
item Kapczynski, Darrell

Submitted to: American Association of Avian Pathologist
Publication Type: Abstract Only
Publication Acceptance Date: 3/4/2007
Publication Date: 7/14/2007
Citation: Liljebjelke, K.A., King, D.J., Kapczynski, D.R. 2007. Newcastle disease virus vaccine potency determination [abstract]. In: Proceedings of 2007 American Association of Avian Pathologist Scientific Program, July 14-18, 2007, Washington, DC. p. 46.

Interpretive Summary:

Technical Abstract: Potency of inactivated Newcastle disease virus (NDV) vaccines is determined using vaccination and challenge. If the minimum killed viral antigen necessary for clinical protection can be determined, vaccines meeting or exceeding this dose might be considered of adequate potency. In these studies, correlation between hemagglutinin (HA) units per dose and protection from clinical disease was determined. The 50 percent protective dose (PD50) of an in-house vaccine and a commercially licensed vaccine were determined using the Office International des Epizooties (OIE) approved method for testing vaccine potency. Results provide guidelines for minimum HA content for inactivated NDV vaccines necessary to ensure potency.